Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism (Q37898706)

25 August 2017

1 reference

title

Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism (English)

1 reference

25 August 2017

Stefano Porcelli

1

0 references

Chiara Fabbri

object named as

Chiara Fabbri

2

0 references

Alessandro Serretti

object named as

Alessandro Serretti

4

0 references

Edoardo Spina

object named as

Edoardo Spina

3

0 references

author name string

Diana De Ronchi

5

1 reference

PubMed ID

21736534

25 August 2017

language of work or name

English

0 references

publication date

8 July 2011

1 reference

Expert Opinion on Drug Metabolism & Toxicology

25 August 2017

1 reference

25 August 2017

7

1 reference

25 August 2017

9

1 reference

25 August 2017

1101-1115

1 reference

The impact of CYP allelic variation on antidepressant metabolism: a review

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Molecular genetics of the human cytochrome P450 monooxygenase superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean m

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Interaction study between enoxacin and fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Enantioselective analysis of citalopram and metabolites in adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Quantitative pharmacogenetics of nortriptyline: a novel approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Sequence-based CYP2D6 genotyping in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Population pharmacokinetic analysis of mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effect of age, weight, and CYP2C19 genotype on escitalopram exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Non-linear fluvoxamine disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Pharmacogenetics of antidepressant medication intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Pharmacogenetic investigation of smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Agomelatine treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Cytochrome P450 enzymes contributing to demethylation of maprotiline in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

Epileptiform Seizure After Sertraline Treatment in an Adolescent Experiencing Obsessive-Compulsive Disorder and Presenting a Rare Pharmacogenetic Status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.597740

10.1517/17425255.2011.597740

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21736534